Agrochemicals company Astec Lifesciences announced Q1FY26 results The Company reported consolidated total income of Rs 91.6 crore in Q1FY26 as compared to Rs 70.3 crore in Q1FY25. The consolidated total income in Q1FY 26 increased by 30.3% over Q1 FY25. The Company reported consolidated EBITDA loss of Rs 10.5 crore in Q1FY26 as compared to loss of Rs 45.3 crore in the same period last year. Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively. This also resulted in reduction of EBITDA losses as compared to Q1 FY25, which also had an impact of write down of Inventories of Rs 18.5 crore. Result PDF
Agrochemicals company Astec Lifesciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: The Company reported consolidated total income of Rs 120.3 crore in Q4FY25 as compared to Rs 155.8 crore in Q4FY24. Sequentially, the consolidated total income in Q4FY25 was higher by 25.6% over Q3FY25. The Company reported consolidated EBITDA of Rs 6.3 crore in Q4FY25 as compared to Rs 14.8 crore in Q4FY24. EBIDTA for Q4FY25 showed a sequential improvement over Q3FY25. PAT: Rs -16.1 crore compared to Rs -40.4 crore during Q3FY25. FY25 Financial Highlights: The Company reported consolidated total income of Rs 386.9 crore in FY25 as compared to Rs 463.8 crore in FY24. The Company reported consolidated EBITDA loss of Rs 60.6 crore in FY25 as compared to loss of Rs 0.3 crore in the same period last year. N. B. Godrej, Chairman, Astec LifeSciences, said: In Q4 FY25 Astec reported sequential improvement in performance. EBITDA for Q4FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business. We expect uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year. Result PDF
Agrochemicals company Astec Lifesciences announced Q3FY25 results Q3FY25 Financial Highlights: Consolidated total income in Q3FY25 was Rs 95.8 crore as compared to Rs 51.7 crore in Q3FY24. Consolidated EBITDA loss was Rs 3.8 crore in Q3FY25 as compared to loss of Rs 17.4 crore in Q3FY24. N B Godrej, Chairman, Astec LifeSciences, said: In Q3FY25, Astec reported sequential improvement in performance, narrowing EBITDA losses from Rs 17.7 crore in Q2 FY25 to Rs 3.8 crore in Q3FY25. This positive trend was primarily due to a sequential increase in volumes in our Contract Development and Manufacturing Organization (CDMO) business. However, this positive impact was offset by continued lower realizations in key Enterprise products.Moreover, our EBITDA losses also narrowed from Rs 17.4 crore in Q3FY24 to Rs 3.8 crore in Q3FY25. Result PDF
Agrochemicals company Astec Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Consolidated total income in Q2FY25 was Rs 100.5 crore as compared to Rs 111.8 crore in Q2FY24. Consolidated EBITDA loss was Rs 17.7 crore in Q2FY25 as compared to loss of Rs 2.4 crore in Q2FY24. H1FY25 Financial Highlights: In H1FY25, company reported consolidated total income of Rs 170.8 crore as compared to Rs 256.3 crore in H1FY24. In H1FY25, company reported consolidated EBITDA loss of Rs 63.1 crore as compared to profit of Rs 2.4 crore in H1FY24. N B Godrej, Chairman, Astec LifeSciences, said: In Q2FY25, Astec experienced a modest improvement in volumes within the Enterprise portfolio as compared to Q2FY24, but this positive impact was offset by lower realizations in key Enterprise products due to Chinese overcapacity and inventory destocking. This adversely impacted topline and profitability. In addition, a cautious approach adopted by CDMO customersfurther exacerbated the decline in our topline and profitability compared to Q2FY24. Result PDF
Agrochemicals company Astec Lifesciences announced Q1FY25 results: Financial Highlights: Company reported consolidated total income of Rs 70.3 crore in Q1FY25 as compared to Rs 144.6 crore in Q1FY24 Company reported consolidated EBITDA loss of Rs 45.3 crore in Q1FY25 as compared to profit of Rs 4.8 crore in the same period last year Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: Astec continued to face pricing and demand headwinds in the enterprise products on account of destocking of the inventory across key markets. Challenging external environment necessitated write down of inventory which also significantly impacted the margins of the enterprise portfolio. Also, global logistics issues resulted in delay in receipt of essential raw materials for our Contract Manufacturing (CDMO) product which resulted in deferral of volumes. This unfortunate situation further compressed overall profit margins. Result PDF
Agrochemicals company Astec Lifesciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: The Company reported consolidated total income of Rs 155.8 crore in Q4FY24 as compared to Rs 129.5 crore in Q4FY23 The Company reported consolidated EBITDA of Rs 14.8 crore in Q4FY24 as compared to Rs8.0 crore in the same period last year FY24 Financial Highlights: The Company reported consolidated total income of Rs 463.8 crore in FY24 as compared to Rs 641.2 crore in FY23 The Company reported consolidated EBITDA loss of Rs 0.3 crore in FY24 as compared to profit of Rs 89.3 crore in the same period last year Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences Limited, said:" Astec witnessed a slowdown in its enterprise products portfolio in both domestic as well as global markets. Contract manufacturing (CMO) along with new products development performance, however, was in line with our expectations. Revenues from this segment grew 57% in the quarter due to new product development. During the quarter, Astec maintained a steady focus on new product development along with strategic commitment to long-term R&D; projects." Result PDF